Report seeks to integrate microbes into climate models

Public release date: 14-Feb-2012
[ | E-mail | Share ]

Contact: Jim Sliwa
jsliwa@asmusa.org
202-942-9297
American Society for Microbiology

The models used to understand how Earth's climate works include thousands of different variables from many scientific including atmospherics, oceanography, seismology, geology, physics and chemistry, but few take into consideration the vast effect that microbes have on climate. Now, a new report from the American Academy of Microbiology, "Incorporating Microbial Processes into Climate Models", offers a plan for integrating the latest understanding of the science of microbiology into climate models.

"Climate scientists and microbiologists usually work in isolation from each other, and yet their work is intimately connected. Microbes are critical players in every geochemical cycle relevant to climate. The sum total of microbial activity is enormous, but the net effect of microbes on climate-relevant gases is currently not known," says Edward DeLong of the Massachusetts Institute of Technology, who co-chaired the report with Caroline Harwood of the University of Washington.

The past two decades have witnessed an explosion in scientific recognition of the diversity of the microbial world. New DNA-sequencing technologies spurred by the Human Genome Project have made it technically and economically possible to sequence the collective DNA from whole microbial communities. This approach, called metagenomics, has revealed a previously undreamed-of degree of diversity in the microbial world. These microbial community analyses many "'omics" approaches, such as proteomics and metabolomics, that together provide a detailed picture of community function, potential and change over time.

The report is based on a colloquium convened by the Academy in 2011. Experts in diverse disciplines in microbiology as well as computational and climate modeling participated in the meeting designed to identify specific efforts and activities that will lead to improved integration of microbial biology, biogeochemistry, and climate modeling.

"While the gap between these disciplines is daunting, the need to bridge it is urgent and the science and technology needed to begin to do so is within reach," says Harwood.

The report suggests a multipronged approach, breaking the challenge into manageable parts. The first recommendation is to choose a few specific biogeochemical cycles that are important, microbially driven and tractable to serve as demonstration projects. Specifically, the report identifies methane, carbon storage and nitrous oxide.

Other recommendations include:

Assess current data collection methodologies and develop a monitoring/data collection strategy Implement validation processes to integrate data collection, modeling and experimentation Facilitate and provide incentives for collaborations and interdisciplinary training Address technology needs

"There is clear evidence that microbes can have an enormous impact on climate.. In light of the increasingly urgent need to understand and find ways to mitigate climate change, the centrality of microbes in global biogeochemical cycles, can no longer be ignored," says DeLong.

###

A full copy of the report and more detailed recommendations can be found on the Academy website at http://bit.ly/aamclimate.

The American Academy of Microbiology is the honorific leadership group of the American Society for Microbiology. The mission of the Academy is to recognize scientific excellence, as well as foster knowledge and understanding in the microbiological sciences. A full list of Academy colloquia reports can be found at http://academy.asm.org/colloquia. For more information about the American Society for Microbiology, visit http://www.asm.org.

[ | E-mail | Share ]

 

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

The rest is here:
Report seeks to integrate microbes into climate models

Emerging Microbiology Tests and Companies Developing New Technologies and Products

NEW YORK, Feb. 14, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Emerging Microbiology Tests and Companies Developing New Technologies and Products

http://www.reportlinker.com/p0771110/Emerging-Microbiology-Tests-and-Companies-Developing-New-Technologies-and-Products.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

This 650-page report provides a comprehensive marketing and technological assessment, as well as medical rationale and diagnostic prospects for nearly 80 infectious diseases and viruses, including their scientific background, clinical significance and market needs for both current and emerging tests, vaccines, drugs and extensive listings of companies developing or marketing new technologies and products.

Contains 650 pages and 47 tables

Table of Contents

1. AIDS

a. Background

0 Structure and Composition

0 Classification

0 Origin of AIDS

0 Animal Lentivirus Systems

0 Virus Receptos

0 HIV Infections in Humans

- Pathogenesis & Pathology: Overview of

HIV Infection Course

0 CD4T Lymphocytes and Memory Cells

0 Monocytes and Macrophages

0 Lymphoid Organs

0 Neural Cells

0 Viral Coinfections

- Clinical Findings

0 Plasma Viral Load

0 Pediatric AIDS

- Neurologic Disease

- Opportunistic Infections

- Cancer

0 Immunity

- Virus Isolation

- Serology

- Detection of Viral Nucleic

Acid and Antigens

0 Infectivity

0 Epidemiology

- Worldwide Spread of AIDS

- United States

- Routes of Transmission

b. Diagnostic Tests0 Laboratory Diagnosis- Enzyme Immunoassay Interpretation- Specific, Sensitivity, and PredictiveValue of Enzyme Immunoassays0 Competition Assays0 Western Blot Technique0 Immuno-Fluorescence Assay (IFA)0 Radioimmunoprecipitation0 HIV-1/HIV-2 Combination Testing0 Methods of HIV-Antigen Detection0 Antigen Assays and Blood Screening0 Urine Tests0 Immunopathogenic Mechanism of HIV Infection0 DNA Probes- Overview- Quantitative Polymerase Chain Reaction- In Situ PCR- Needed Improvements0 Viral Load/Drug Resistance Testing0 Genotype and Phenotype Testing0 Blood Banking Considerationc. Vaccines and Drugs- Antiviral Drugs- Vaccines Against HIV0 Transmission of HIV in Blood Products0 HIV Transmission in Transplant andArtificial Insemination Recipients2. Adenovirusa. Backgroundb. Diagnostic Testsc. Vaccines and Drugsd. Adeno-Associated Viruses(AAV)3. Aeromonasa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs4. Anthrax/Bacillus Anthracisa. Background

b. Diagnostic Tests

c. Vaccines and Drugs

5. Arboviruses

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

6. Babesiosis

a. Background

7. Bacillary Epithelioid Angiomatosis (BEA)

And Other Bartonella (Rochalimaea)

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

8. Blastocystis Hominis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

9. Brucella

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

10. Campylobacter

a. Background

b. Diagnostic Tests

0 Identification from Culture

c. Vaccines and Drugs

11. Candida

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

12. Chagas Disease

a. Background

13. Chancroid

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

14. Chlamydia

a. Background

0 Chlamydia Psittaci

0 Chlamydia Pneumoniae0 Chlamydia Trachomatisb. Diagnostic Testsc. Vaccines and Drugs15. Clostridium Difficilea. Background0 Pediatric Infections0 Epidemiologyb. Diagnostic Tests0 Counterimmunoelectrophoresis0 Fluorescent-Antibody Assays0 Poloymerase Chain Reactionsc. Drugs and Vaccines16. Coronavirusesa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs17. Coxsackievirusesa. Background0 Herpangina0 Hand-foot-and-mouth syndrome0 Hepidemic Conjuctivitis0 Pharingitis0 Epidemic Pleurodynia0 Myodarditis,Pericarditis0 Overwhelming Infection of the Newborn0 Acute Aseptic Meningitis0 Undifferentiated Febrile Illness0 Fever with upper respiratory infection0 Encephalitis0 Asymptomatic Infectionb. Diagnostic Testsc. Vaccines and Drugs18. Creutzfeldt-Jakob's Diseasea. Background0 Blood Transmissionb. Diagnostic Tests0 Major Commercial and Academic Players- Bayer

- Disease Sciences/Bio Tec Global

- Imperial College of Medicine

- Ortho-Clinical Diagnostics

- Pall

- ProMetic Life Sciences

- Proteome Sciences/Idexx

- Q-One Biotech

- Serono

- U.S. Agricultural Research Service

c. Vaccines

19. Cryptosporidium Parvum

a. Background

b. Diagnostic Tests

0 Histologic

0 Laboratory Parasitology

0 Serodiagnosis

c. Vaccines and Drugs

20. Cyclospora Cayetanensis

a. Background

0 Asymptomatic Infection

0 Diarrhea in Immunocompetent Persons

0 Diarrhea in Immunocompromisedersons

b. Diagnostic Tests

c. Vaccines and Drugs

21. Cytomegalovirus

a. Background

0 Chorioretinitis

0 Gastrointestinal

0 Central Nervous System Disease

b. Diagnostic Tests

c. Vaccines and Drugs

22. Ebola Virus

a. Background

0 Epidemiology

0 Hemorrhagic Fever

b. Diagnostic Tests

c. Vaccines and Drugs

23. E. Coli

a. Background

0 Role of Escherichia Coli inCausing Diarrhea0 EPEC0 ETEC0 EIEC0 EHECb. Diagnostic Testsc. Vaccines and Drugs24. EchoVirusa. Background0 Acute Aseptic Miningitisis0 Encephalitis0 Exanthems0 Respiratory Disease0 Myope;ricarditis0 Neonatal Infectionsb. Diagnostic Testsc. Vaccines and Drugs25. Encephalitisa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs26. Enterovirusesa. Backgroundb. Diagnostic Tests0 Viral Isolation and Identification0 Antibody Testsc. Vaccines and Drugs27. Epstein-Barr Virusa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs28. Giardia Lambliaa. Background0 Life Cycle and Morphology0 Morphology of Trophozoites0 Clinical Diseaseb. Diagnostic Testsc. Vaccines and Drugs

29. Gonorrhea

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

30. Granuloma Inguinale

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

31. Hantavirus

a. Background

0 Identification of the Agent

0 Transmission

0 Other Rodent Hantaviruses

0 Distribution

0 Hantavirus Diseases

0 Epidemiology

0 Addendum in Proof-Northeastern Connection

0 Previously Unknown Pathogens

0 Cases Nationwide

b. Diagnostic Tests

0 An Immunohistochemistry Approach

0 Hantavirus Rapid Diagnostic Test

0 ELISA Diagnosis of Hantavirus Pulmonary

Syndrome

0 IgG ELISA

0 IgM Capture ELISA

c. Vaccines and Drugs

32. Helicobacter Pylori

a. Background

0 Pathogenesis

0 Role in Peptic Ulcer Disease

0 Role in Gastric Cancer

0 Nonulcer Dyspepsia

b. Diagnostic Tests

c. Vaccines and Drugs

0 Specific Therapeutic Regimens

0 Who Should Be Treated?

0 Participants in Controlled Clinical Trials

0 Patients with Refractory Peptic Ulcer0 Patients with Refractory NUD0 Patients in High-Risk Groups for GastricCancer33. Hepatitisa. Backgroundb. Hepatitis Ac. Hepatitis Bd. Hepatitis C0 Classification0 Transmission of Infection0 Occupational Hazards0 Acute Hepatitis0 Diagnosis of Acute Infection0 Chronic Hepatitis0 HCV and Other Chronic Liver Diseases0 Alcoholic Liver Disease0 Hepatitis B Coinfection0 Cirrhosis and Hepatocellular Carcinoma0 Diagnostic Tests0 Possible Indications for HCV RNA Testing0 Conclusions and Future Directione. Hepatitis D0 Historical Perspective0 Epidemiology0 HBV-HDV "Coinfection" vs. "Superinfection"0 Methods of Detecting HDV0 Preventionf. Hepatitis E0 Background0 Prevalence of the Disease0 Diagnostic Tests0 Epidemiologic Serosurveys0 Serologic Cross-Reactivityg. Hepatitis G0 Vaccines and Drugs34. Herpes Simplex Virusa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs

35. Human Herpes Virus-6 (HHV-6)

a. Background

0 HIV-6 Infections

b. Diagnostic Tests

c. Vaccines and Drugs

36. Influenza Viruses

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

37. Legionella

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

38. Lyme Disease

a. Background

0 Clinical Description

0 Clinical Case Definition

0 Laboratory Criteria for Diagnosis

0 Case Classification

b. Diagnostic Tests

c. Vaccines and Drugs

39. Lymphogranuloma Venereum (LGV)

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

40. Malaria

a. Background

b. Diagnostic Tests

0 Potential Diagnositic Problems with Positive

Patients from Non-endemic Areas

- Patient

- Laboratory

- Physician

c. Vaccines and Drugs

41. Measles (Rubeola)

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

42. Meningitisa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs0 Development of Polysaccharide Vaccines0 Quadrivalent Vaccine Development0 Meningococcal A.C.Y. & W-135 Vaccines0 Efficacy of Group C Vaccine0 Efficacy of Group A Vaccine0 Combinations of Group A and C Vaccines0 Group B Efficacy Trials0 Future Direction43. Microsporidiuma. Background0 Prevalence and Geographic Distribution0 Sources of Human Infection and Transmissionb. Diagnostic Tests0 Light Microscopic Examination of StoolSpecimens By Chromotrope Staining0 Stool Concentration Methods0 Chemofluorescent Agents0 Giemsa Staining of Stool Specimens0 Cytologic Diagnosis0 Histologic Examination0 Electron Microscopy0 Examination of Bodily Fluids0 Examination of Tissue Sections0 Immunofluorescence Detection Procedures0 Serology0 Cell Culture0 Approach to Diagnosis0 Evaluation of Patients with PresumptiveIntestinal Microsporidiosis0 Evaluation of Patients with PresumptiveOcular Microsporidiosisc. Vaccines and Drugs44. Mononucleosisa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs

45. Mumps

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

0 Efficacy of Vaccination

0 Future Issues

46. Mycoplasma

a. Background

0 Ureaplasma Urealyticum & Mycoplasma Hominis

b. Diagnostic Tests

c. Vaccines and Drugs

47. Papillomaviruses

a. Background

0 HPV in Cancer

0 Cervical Neoplasm

b. Diagnostic Tests

c. Vaccines and Drugs

0 Prevention

48. Parvovirus B19

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

49. Pneumonia

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

50. Polyomaviruses

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

51. Pseudomonas Aeruginosa

a. Background

0 Virulence Factors

b. Diagnostic Tests

c. Vaccines and Drugs

52. Rabies

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

53. Respiratory Syncytial Virus (RSV)a. Backgroundb. Diagnostic Testsc. Vaccines and Drugs54. RhinoVirusesa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs55. RotaVirus (REOVIRUS)a. Backgroundb. Diagnostic Testsc. Vaccines and Drugs56. Rubella(MEASLES)a. Backgroundb. Diagnostic Testsc. Vaccines and Drugs0 Developing Countries0 Elimination and Eradication of Measles0 New Developments57. Salmonellosisa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs58. Septicemiaa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs59. Shigellosisa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs60. Staphylococcus Aureusa. Background0 The Genus Taphylococcusb. Diagnostic Testsc. Vaccines and Drugs0 Prevention61. Streptococcia. Backgroundb. Diagnostic Tests

c. Vaccines and Drugs

0 Group A Streptococci

0 Group B Streptococci

62. Syphilis

a. Background

b. Diagnostic Tests

0 Biopsy

0 Rabbit Infectivity Testing

0 Other Diagnostic Modalities

c. Vaccines and Drugs

0 Syphilis and HIV Infection

0 Syphilis As a Cofactor for HIV Transmission

0 Basic Science Issues

63. Toxoplasmosis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

64. Trichomonas Vaginalis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

65. Tuberculosis

a. Background

b. Diagnostic Tests

0 Microscopic Characteristics

0 Cultural Characteristics

0 Detection of Antibodies

0 Skin Tests

0 MDRTB

c. Vaccines and Drugs

66. Vibrio

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

67. West Nile Virus

a. Background

- Clinical Syndromes

b. Diagnostic Tests

c. Vaccines and Drugs

68. Yersinaa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs

List of Tables

Major Companies Developing or Marketing AIDS TestsMajor Companies Developing or Marketing AdenovirusTestsMajor Companies Developing or Marketing BartonellaTestsMajor Companies Developing or MarketingCampylobacter TestsMajor Companies Developing or Marketing CandidaTestsMajor Companies Developing or Marketing ChlamydiaTestsMajor Companies Developing or Marketing ClostridiumTestsMajor Companies Developing or Marketing CoronavirusTestsMajor Companies Developing or Marketing CryptosporidiumTestsMajor Companies Developing or Marketing CMV TestsMajor Companies Developing or Marketing EchovirusTestsMajor Companies Developing or Marketing EnterovirusTestsMajor Companies Developing or Marketing EBV Tests

Major Companies Developing or Marketing Giardia

Tests

Major Companies Developing or Marketing Gonorrhea

Tests

Major Companies Developing or Marketing Hantavirus

Tests

Major Companies Developing or Marketing Helicobacter

Pylori Tests

Major Companies Developing or Marketing Hepatitis

Tests

Major Companies Developing or Marketing Herpes

Tests

Major Companies Developing or Marketing Influenza

Tests

Major Companies Developing or Marketing Legionella

Tests

Major Companies Developing or Marketing Lyme Disease

Tests

Major Companies Developing or Marketing Lymphogranuloma

Tests

Major Companies Developing or Marketing Malaria

Tests

Major Companies Developing or Marketing Measles

Tests

Major Companies Developing or Marketing Meningitis

Tests

Major Companies Developing or Marketing MicrosporidiumTestsMajor Companies Developing or MarketingMononucleosis TestsMajor Companies Developing or Marketing Mumps TestsMajor Companies Developing or Marketing MycoplasmaTestsMajor Companies Developing or Marketing PapillomaVirus TestsMajor Companies Developing or Marketing ParvovirusTestsMajor Companies Developing or Marketing PneumoniaTestsMajor Companies Developing or Marketing RSV TestsMajor Companies Developing or Marketing RotavirusTestsMajor Companies Developing or Marketing RubellaTestsMajor Companies Developing or Marketing SalmonellaTestsMajor Companies Developing or Marketing SepticemiaTestsMajor Companies Developing or Marketing ShigellaTestsMajor Companies Developing or Marketing StaphylococciTests

Major Companies Developing or Marketing

Streptococci Tests

Major Companies Developing or Marketing Syphilis

Tests

Major Companies Developing or Marketing Toxoplasmosis

Tests

Major Companies Developing or Marketing Trichomonas

Tests

Major Companies Developing or Marketing Tuberculosis

Tests

Major Companies Developing or Marketing West Nile

Tests

Major Companies Developing or Marketing Yersinia Tests

To order this report:In Vitro Diagnostic Industry: Emerging Microbiology Tests and Companies Developing New Technologies and Products

More  

Market Research Report

Check our  

Industry Analysis and Insights

 

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

Read this article:
Emerging Microbiology Tests and Companies Developing New Technologies and Products

Future Microbiology Testing Market: Facilities, Test Volumes, and Sales Forecasts by Country

NEW YORK, Feb. 14, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Future Microbiology Testing Market: Facilities, Test Volumes, and Sales Forecasts by Country

http://www.reportlinker.com/p0771111/Future-Microbiology-Testing-Market-Facilities-Test-Volumes-and-Sales-Forecasts-by-Country.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

This report provides a worldwide overview of the microbiology testing market environment, structure, size and growth. Includes estimates of the number of laboratories performing microbiology tests, as well as ten-year test volume and sales forecasts by country.

Contains 15 pages and 3 tables

Table of Contents1. Worldwide Business Environment

2. Worldwide Market Structure

3. Worldwide Market Size and Growth

List of TablesTable 1: Laboratories Performing Microbiology Tests by Country

Table 2: Total Microbiology Test Volume Forecast by Country

Table 3: Total Microbiology Diagnostics Market Forecast by Country

To order this report:In Vitro Diagnostic Industry: Future Microbiology Testing Market: Facilities, Test Volumes, and Sales Forecasts by Country

More  

Market Research Report

Check our  

Industry Analysis and Insights

CONTACT
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

 

See the article here:
Future Microbiology Testing Market: Facilities, Test Volumes, and Sales Forecasts by Country

Future US Microbiology Testing Market Outlook

NEW YORK, Feb. 14, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Future US Microbiology Testing Market Outlook

http://www.reportlinker.com/p0771120/Future-US-Microbiology-Testing-Market-Outlook.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

Complete report $9,400.  DataPack (test volumes, sales forecasts, supplier shares) $3,450.

Highlights

Comprehensive 1,037-page analysis of the US microbiology testing market. Major issues pertaining to the US microbiology laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. Current scientific views on the definition, epidemiology, and etiology of major infectious diseases and microorganisms. Ten-year test volume and sales forecasts for nearly 80 microbiology tests performed in US hospitals, blood banks, physician offices, public health and commercial laboratories. Instrumentation technologies and feature comparison of leading analyzers. Sales and market shares of leading suppliers. Emerging diagnostic technologies and their potential market applications. Product development opportunities. Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. Business opportunities and strategic recommendations for suppliers.

Contains 1,037 pages and 177 tables

US MICROBIOLOGY TESTING MARKETTable of ContentsIntroductionWorldwide Market and Technology OverviewA. Major Infectious Disease Tests1. AIDSa. Background0 Structure and Composition0 Classification0 Origin of AIDS0 Animal Lentivirus Systems0 Virus Receptos0 HIV Infections in Humans- Pathogenesis & Pathology: Overview ofHIV Infection Course0 CD4T Lymphocytes and Memory Cells0 Monocytes and Macrophages0 Lymphoid Organs0 Neural Cells0 Viral Coinfections- Clinical Findings0 Plasma Viral Load0 Pediatric AIDS- Neurologic Disease- Opportunistic Infections- Cancer0 Immunity- Virus Isolation- Serology- Detection of Viral NucleicAcid and Antigens0 Infectivity0 Epidemiology- Worldwide Spread of AIDS- United States- Routes of Transmission

b. Diagnostic Tests

0 Laboratory Diagnosis

- Enzyme Immunoassay Interpretation

- Specific, Sensitivity, and Predictive

Value of Enzyme Immunoassays

0 Competition Assays

0 Western Blot Technique

0 Immuno-Fluorescence Assay (IFA)

0 Radioimmunoprecipitation

0 HIV-1/HIV-2 Combination Testing

0 Methods of HIV-Antigen Detection

0 Antigen Assays and Blood Screening

0 Urine Tests

0 Immunopathogenic Mechanism of HIV Infection

0 DNA Probes

- Overview

- Quantitative Polymerase Chain Reaction

- In Situ PCR

- Needed Improvements

0 Viral Load/Drug Resistance Testing

0 Genotype and Phenotype Testing

0 Blood Banking Consideration

c. Vaccines and Drugs

- Antiviral Drugs

- Vaccines Against HIV

0 Transmission of HIV in Blood Products

0 HIV Transmission in Transplant and

Artificial Insemination Recipients

2. Adenovirus

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

d. Adeno-Associated Viruses(AAV)

3. Aeromonas

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

4. Anthrax/Bacillus Anthracis

a. Background

b. Diagnostic Testsc. Vaccines and Drugs5. Arbovirusesa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs6. Babesiosisa. Background7. Bacillary Epithelioid Angiomatosis (BEA)And Other Bartonella (Rochalimaea)a. Backgroundb. Diagnostic Testsc. Vaccines and Drugs8. Blastocystis Hominisa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs9. Brucellaa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs10. Campylobactera. Backgroundb. Diagnostic Tests0 Identification from Culturec. Vaccines and Drugs11. Candidaa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs12. Chagas Diseasea. Background13. Chancroida. Backgroundb. Diagnostic Testsc. Vaccines and Drugs14. Chlamydiaa. Background0 Chlamydia Psittaci

0 Chlamydia Pneumoniae

0 Chlamydia Trachomatis

b. Diagnostic Tests

c. Vaccines and Drugs

15. Clostridium Difficile

a. Background

0 Pediatric Infections

0 Epidemiology

b. Diagnostic Tests

0 Counterimmunoelectrophoresis

0 Fluorescent-Antibody Assays

0 Poloymerase Chain Reactions

c. Drugs and Vaccines

16. Coronaviruses

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

17. Coxsackieviruses

a. Background

0 Herpangina

0 Hand-foot-and-mouth syndrome

0 Hepidemic Conjuctivitis

0 Pharingitis

0 Epidemic Pleurodynia

0 Myodarditis,Pericarditis

0 Overwhelming Infection of the Newborn

0 Acute Aseptic Meningitis

0 Undifferentiated Febrile Illness

0 Fever with upper respiratory infection

0 Encephalitis

0 Asymptomatic Infection

b. Diagnostic Tests

c. Vaccines and Drugs

18. Creutzfeldt-Jakob's Disease

a. Background

0 Blood Transmission

b. Diagnostic Tests

0 Major Commercial and Academic Players

- Bayer

- Disease Sciences/Bio Tec Global- Imperial College of Medicine- Ortho-Clinical Diagnostics- Pall- ProMetic Life Sciences- Proteome Sciences/Idexx- Q-One Biotech- Serono- U.S. Agricultural Research Servicec. Vaccines19. Cryptosporidium Parvuma. Backgroundb. Diagnostic Tests0 Histologic0 Laboratory Parasitology0 Serodiagnosisc. Vaccines and Drugs20. Cyclospora Cayetanensisa. Background0 Asymptomatic Infection0 Diarrhea in Immunocompetent Persons0 Diarrhea in Immunocompromisedersonsb. Diagnostic Testsc. Vaccines and Drugs21. Cytomegalovirusa. Background0 Chorioretinitis0 Gastrointestinal0 Central Nervous System Diseaseb. Diagnostic Testsc. Vaccines and Drugs22. Ebola Virusa. Background0 Epidemiology0 Hemorrhagic Feverb. Diagnostic Testsc. Vaccines and Drugs23. E. Colia. Background

0 Role of Escherichia Coli in

Causing Diarrhea

0 EPEC

0 ETEC

0 EIEC

0 EHEC

b. Diagnostic Tests

c. Vaccines and Drugs

24. EchoVirus

a. Background

0 Acute Aseptic Miningitisis

0 Encephalitis

0 Exanthems

0 Respiratory Disease

0 Myope;ricarditis

0 Neonatal Infections

b. Diagnostic Tests

c. Vaccines and Drugs

25. Encephalitis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

26. Enteroviruses

a. Background

b. Diagnostic Tests

0 Viral Isolation and Identification

0 Antibody Tests

c. Vaccines and Drugs

27. Epstein-Barr Virus

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

28. Giardia Lamblia

a. Background

0 Life Cycle and Morphology

0 Morphology of Trophozoites

0 Clinical Disease

b. Diagnostic Tests

c. Vaccines and Drugs

29. Gonorrheaa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs30. Granuloma Inguinalea. Backgroundb. Diagnostic Testsc. Vaccines and Drugs31. Hantavirusa. Background0 Identification of the Agent0 Transmission0 Other Rodent Hantaviruses0 Distribution0 Hantavirus Diseases0 Epidemiology0 Addendum in Proof-Northeastern Connection0 Previously Unknown Pathogens0 Cases Nationwideb. Diagnostic Tests0 An Immunohistochemistry Approach0 Hantavirus Rapid Diagnostic Test0 ELISA Diagnosis of Hantavirus PulmonarySyndrome0 IgG ELISA0 IgM Capture ELISAc. Vaccines and Drugs32. Helicobacter Pyloria. Background0 Pathogenesis0 Role in Peptic Ulcer Disease0 Role in Gastric Cancer0 Nonulcer Dyspepsiab. Diagnostic Testsc. Vaccines and Drugs0 Specific Therapeutic Regimens0 Who Should Be Treated?0 Participants in Controlled Clinical Trials

0 Patients with Refractory Peptic Ulcer

0 Patients with Refractory NUD

0 Patients in High-Risk Groups for Gastric

Cancer

33. Hepatitis

a. Background

b. Hepatitis A

c. Hepatitis B

d. Hepatitis C

0 Classification

0 Transmission of Infection

0 Occupational Hazards

0 Acute Hepatitis

0 Diagnosis of Acute Infection

0 Chronic Hepatitis

0 HCV and Other Chronic Liver Diseases

0 Alcoholic Liver Disease

0 Hepatitis B Coinfection

0 Cirrhosis and Hepatocellular Carcinoma

0 Diagnostic Tests

0 Possible Indications for HCV RNA Testing

0 Conclusions and Future Direction

e. Hepatitis D

0 Historical Perspective

0 Epidemiology

0 HBV-HDV "Coinfection" vs. "Superinfection"

0 Methods of Detecting HDV

0 Prevention

f. Hepatitis E

0 Background

0 Prevalence of the Disease

0 Diagnostic Tests

0 Epidemiologic Serosurveys

0 Serologic Cross-Reactivity

g. Hepatitis G

0 Vaccines and Drugs

34. Herpes Simplex Virus

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

35. Human Herpes Virus-6 (HHV-6)a. Background0 HIV-6 Infectionsb. Diagnostic Testsc. Vaccines and Drugs36. Influenza Virusesa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs37. Legionellaa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs38. Lyme Diseasea. Background0 Clinical Description0 Clinical Case Definition0 Laboratory Criteria for Diagnosis0 Case Classificationb. Diagnostic Testsc. Vaccines and Drugs39. Lymphogranuloma Venereum (LGV)a. Backgroundb. Diagnostic Testsc. Vaccines and Drugs40. Malariaa. Backgroundb. Diagnostic Tests0 Potential Diagnositic Problems with PositivePatients from Non-endemic Areas- Patient- Laboratory- Physicianc. Vaccines and Drugs41. Measles (Rubeola)a. Backgroundb. Diagnostic Testsc. Vaccines and Drugs

42. Meningitis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

0 Development of Polysaccharide Vaccines

0 Quadrivalent Vaccine Development

0 Meningococcal A.C.Y. & W-135 Vaccines

0 Efficacy of Group C Vaccine

0 Efficacy of Group A Vaccine

0 Combinations of Group A and C Vaccines

0 Group B Efficacy Trials

0 Future Direction

43. Microsporidium

a. Background

0 Prevalence and Geographic Distribution

0 Sources of Human Infection and Transmission

b. Diagnostic Tests

0 Light Microscopic Examination of Stool

Specimens By Chromotrope Staining

0 Stool Concentration Methods

0 Chemofluorescent Agents

0 Giemsa Staining of Stool Specimens

0 Cytologic Diagnosis

0 Histologic Examination

0 Electron Microscopy

0 Examination of Bodily Fluids

0 Examination of Tissue Sections

0 Immunofluorescence Detection Procedures

0 Serology

0 Cell Culture

0 Approach to Diagnosis

0 Evaluation of Patients with Presumptive

Intestinal Microsporidiosis

0 Evaluation of Patients with Presumptive

Ocular Microsporidiosis

c. Vaccines and Drugs

44. Mononucleosis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

45. Mumpsa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs0 Efficacy of Vaccination0 Future Issues46. Mycoplasmaa. Background0 Ureaplasma Urealyticum & Mycoplasma Hominisb. Diagnostic Testsc. Vaccines and Drugs47. Papillomavirusesa. Background0 HPV in Cancer0 Cervical Neoplasmb. Diagnostic Testsc. Vaccines and Drugs0 Prevention48. Parvovirus B19a. Backgroundb. Diagnostic Testsc. Vaccines and Drugs49. Pneumoniaa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs50. Polyomavirusesa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs51. Pseudomonas Aeruginosaa. Background0 Virulence Factorsb. Diagnostic Testsc. Vaccines and Drugs52. Rabiesa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs

53. Respiratory Syncytial Virus (RSV)

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

54. RhinoViruses

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

55. RotaVirus (REOVIRUS)

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

56. Rubella(MEASLES)

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

0 Developing Countries

0 Elimination and Eradication of Measles

0 New Developments

57. Salmonellosis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

58. Septicemia

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

59. Shigellosis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

60. Staphylococcus Aureus

a. Background

0 The Genus Taphylococcus

b. Diagnostic Tests

c. Vaccines and Drugs

0 Prevention

61. Streptococci

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs0 Group A Streptococci0 Group B Streptococci62. Syphilisa. Backgroundb. Diagnostic Tests0 Biopsy0 Rabbit Infectivity Testing0 Other Diagnostic Modalitiesc. Vaccines and Drugs0 Syphilis and HIV Infection0 Syphilis As a Cofactor for HIV Transmission0 Basic Science Issues63. Toxoplasmosisa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs64. Trichomonas Vaginalisa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs65. Tuberculosisa. Backgroundb. Diagnostic Tests0 Microscopic Characteristics0 Cultural Characteristics0 Detection of Antibodies0 Skin Tests0 MDRTBc. Vaccines and Drugs66. Vibrioa. Backgroundb. Diagnostic Testsc. Vaccines and Drugs67. West Nile Virusa. Background- Clinical Syndromesb. Diagnostic Testsc. Vaccines and Drugs

68. Yersina

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

B. Instrumentation Review and Market Needs

0 Abbott AxSYM

0 Abbott IMx/IMx Select

0 Anagen AN2000/AuraFlex

0 Beckman Coulter Access

0 BioChem Pharma/SR1

0 BioMerieux/Vitek Vidas

0 Biotrol System 7000

0 Chiron ACS: Centaur

0 Chiron ACS: 180

0 J&J Diagnostics/Amersham Amerlite

0 J&J Diagnostics Vitros ECi

0 Olympus PK310

0 Roche Cobas Core

0 Roche Elecsys 1010/2010

0 Roche ES 22

0 Roche ES 33

0 Roche ES 300/300AL

0 Siemens ELISA Processor II/III

0 Siemens Immuno 1

0 Siemens/Opus/Plus/Magnum

0 Siemens Stratus

0 Tosoh AIA-1200/1200DX/NexIA/600

0 Wallac/Pharmacia Delfia

C. Emerging Diagnostic Technologies

1. DNA Probes

a. Technology Overview

b. Amplification Methods

0 Polymerase Chain Reaction

- Robotics

- Temperature Cyclers

- PCR Variations

0 Immuno-PCR

0 QC-PCR

0 DAP-PCR

0 Ligase Chain Reaction0 Branched DNA0 Q-Beta Replicase0 Nucleic-Acid Sequence-Based0 Strand Displacement Activation0 Self-Sustained Sequence Replicase2. Monoclonal Antibodies3. Immunoassaysa. Technological Principleb. Enzyme Immunoassays (EIA)0 Overview0 ELISA0 Dot Immunobinding Assays0 Capillary Immunoassays0 Particle-Membrane CaptureImmunoassays0 Enzyme Amplificationc. Fluorescent Immunoassays0 Fluorescence Polarization0 Time-Resolved Pulse Fluorescenced. Luminescence0 Chemiluminescence0 Bioluminescencee. Latex Agglutinationf. Immunoprecipitation4. Differential Light Scattering5. Microcomputers and Automation6. Artificial Intelligence7. Liposomes8. Flow Cytometry9. Chromatography10. MRI11. Gel Microdroplets12. OtherD. Personal TestingE. Worldwide Business EnvironmentF. Worldwide Market StructureG. Worldwide Market Size and Growth

U.S.A.

A. Executive Summary

B. Business Environment

1. Health Care Expenditures

2. Cost Consciousness

3. Reimbursement

4. Industry Consolidation

5. Managed Care

a. HMO

b. PPO

6. Hospitals

7. Admissions

8. Length of Stay

9. Industry Diversification

10. Physician Demographics

11. Population Aging

a. Chronic Illness

b. Disease Incidence

c. Susceptibility to Iatrogenesis

d. Multiple Illness Cases

12. Laboratory Regulations

13. FDA Reform

C. Market Structure

1. Centralized Testing

a. Hospitals

b. Commercial/Private Laboratories

c. Blood Banks

1) Community and Regional Centers

2) Plasma Fractionation Centers

2. Decentralized Testing

a. Physician Offices/Group Practices

b. Point of Care Testing

c. Other Decentralized Testing Locations

D. Market Size, Growth and Major Suppliers

Major Product Development OpportunitiesA. InstrumentationB. Reagent Kits and Test Systems/PanelsC. Computers, Software and AutomationD. Auxiliary ProductsDesign Criteria for Decentralized Testing ProductsAlternative Market Penetration StrategiesA. Internal DevelopmentB. Collaborative ArrangementsC. University ContractsD. Distribution Strategies for DecentralizedTesting Markets1. Marketing Approaches2. Product Complexity3. Customer Preference4. Established Suppliers5. Emerging Suppliers6. Major Types of Distributors7. Market SegmentationPotential Market Entry Barriers and RisksA. Market MaturityB. Cost ContainmentC. CompetitionD. Technological Edge and LimitationsE. Patent ProtectionF. Regulatory ConstraintsG. Decentralized Testing Market ChallengesCompetitive Assessments- Abbott- Affymetrix- Beckman Coulter- Becton Dickinson- bioMerieux

- Bio-Rad

- Cepheid

- Diamedix

- DiaSorin

- Eiken Chemical

- Enzo Biochem

- Fujirebio

- Gen-Probe

- Hologic

- ID Biomedical

- J&J Diagnostics

- Kreatech

- Life Technology

- Lonza

- Nanogen

- Novartis Diagnostics

- Qiagen

- Roche

- Scienion

- Sequenom

- SeraCare

- Siemens

- Takara Bio

- Thermo Fisher

- Wallac

- Wako

List of Tables

Major Companies Developing or Marketing AIDS TestsMajor Companies Developing or Marketing AdenovirusTestsMajor Companies Developing or Marketing BartonellaTestsMajor Companies Developing or MarketingCampylobacter TestsMajor Companies Developing or Marketing CandidaTestsMajor Companies Developing or Marketing ChlamydiaTestsMajor Companies Developing or Marketing ClostridiumTestsMajor Companies Developing or Marketing CoronavirusTestsMajor Companies Developing or Marketing CryptosporidiumTestsMajor Companies Developing or Marketing CMV TestsMajor Companies Developing or Marketing EchovirusTestsMajor Companies Developing or Marketing EnterovirusTestsMajor Companies Developing or Marketing EBV Tests

Major Companies Developing or Marketing Giardia

Tests

Major Companies Developing or Marketing Gonorrhea

Tests

Major Companies Developing or Marketing Hantavirus

Tests

Major Companies Developing or Marketing Helicobacter

Pylori Tests

Major Companies Developing or Marketing Hepatitis

Tests

Major Companies Developing or Marketing Herpes

Tests

Major Companies Developing or Marketing Influenza

Tests

Major Companies Developing or Marketing Legionella

Tests

Major Companies Developing or Marketing Lyme Disease

Tests

Major Companies Developing or Marketing Lymphogranuloma

Tests

Major Companies Developing or Marketing Malaria

Tests

Major Companies Developing or Marketing Measles

Tests

Major Companies Developing or Marketing Meningitis

Tests

Major Companies Developing or Marketing MicrosporidiumTestsMajor Companies Developing or MarketingMononucleosis TestsMajor Companies Developing or Marketing Mumps TestsMajor Companies Developing or Marketing MycoplasmaTestsMajor Companies Developing or Marketing PapillomaVirus TestsMajor Companies Developing or Marketing ParvovirusTestsMajor Companies Developing or Marketing PneumoniaTestsMajor Companies Developing or Marketing RSV TestsMajor Companies Developing or Marketing RotavirusTestsMajor Companies Developing or Marketing RubellaTestsMajor Companies Developing or Marketing SalmonellaTestsMajor Companies Developing or Marketing SepticemiaTestsMajor Companies Developing or Marketing ShigellaTestsMajor Companies Developing or Marketing StaphylococciTests

Major Companies Developing or Marketing

Streptococci Tests

Major Companies Developing or Marketing Syphilis

Tests

Major Companies Developing or Marketing Toxoplasmosis

Tests

Major Companies Developing or Marketing Trichomonas

Tests

Major Companies Developing or Marketing Tuberculosis

Tests

Major Companies Developing or Marketing West Nile

Tests

Major Companies Developing or Marketing Yersinia Tests

Worldwide All Market Segments Laboratories

Performing Microbiology Tests by Country

Worldwide All Market Segments Total Microbiology Test

Volume Forecast by Country

Worldwide All Market Segments Total Microbiology

Diagnostics Market Forecast by Country

Infectious Disease Tests Major Issues and Market

Potential For Personal Testing

U.S.A. Summary Table

All Infectious Diseases Test Volume and Diagnostics

Sales Forecast by Market Segment

U.S.A.

Laboratories Performing Infectious Disease Tests

by Market Segment

U.S.A.Hospital Laboratories Performing Infectious DiseaseTests by Bed SizeU.S.A.Commercial/Private Laboratories Performing InfectiousDisease Tests by Annual Test VolumeU.S.A.Physician Office Laboratories Performing InfectiousDisease Tests by Practice SizeU.S.A.All Market Segments Infectious Disease Test Volume ForecastU.S.A.Hospital Laboratories Infectious Disease Test Volume ForecastU.S.A.Blood Banks Infectious Disease Test Volume ForecastU.S.A.Physician Office Laboratories Infectious DiseaseTest Volume ForecastU.S.A.Commercial/Private Laboratories Infectious DiseaseTest Volume ForecastU.S.A.Public Health Laboratories Infectious Disease TestVolume ForecastU.S.A.All Market Segments Infectious Disease DiagnosticsMarket ForecastU.S.A.Hospital Laboratories Infectious Disease DiagnosticsMarket Forecast

U.S.A.

Blood Banks Infectious Disease Diagnostics Market Forecast

U.S.A.

Physician Office Laboratories Infectious Disease

Diagnostics Market Forecast

U.S.A.

Commercial/Private Laboratories Infectious Disease

Diagnostics Market Forecast

U.S.A.

Public Health Laboratories Infectious Disease

Diagnostics Market Forecast

U.S.A.

HIV or HIVI/HIVII Test Volume and Diagnostics Sales

Forecast by Market Segment

U.S.A.

HTLV I or HTLV I/HTLV II Test Volume and Diagnostics

Sales Forecast by Market Segment

U.S.A.

HIVAg Test Volume and Diagnostics Sales Forecast by Market

Segment

U.S.A.

Western Blot/Other Confirmatory Test Volume and

Diagnostics Sales Forecast by Market Segment

U.S.A.

Adenovirus Test Volume and Diagnostics Sales Forecast by

Market Segment

U.S.A.

Aeromonads Test Volume and Diagnostics Sales Forecast by

Market Segment

U.S.A.BEA Test Volume and Diagnostics Sales Forecast by MarketSegmentU.S.A.Blastocystis Hominis Test Volume and Diagnostics SalesForecast by Market SegmentU.S.A.Campylobacter Test Volume and Diagnostics Sales Forecast byMarket SegmentU.S.A.Candida Test Volume and Diagnostics Sales Forecast by MarketSegmentU.S.A.Chancroid Test Volume and Diagnostics Sales Forecast by MarketSegmentU.S.A.Chlamydia Test Volume and Diagnostics Sales Forecast by MarketSegmentU.S.A.Clostridium Test Volume and Diagnostics Sales Forecast byMarketSegmentU.S.A.Coronavirus Test Volume and Diagnostics Sales Forecast byMarket SegmentU.S.A.CoxsackieVirus Test Volume and Diagnostics Sales Forecast byMarket SegmentU.S.A.Cryptosporidium Test Volume and Diagnostics SalesForecast by Market Segment

U.S.A.

Cyclospora Test Volume and Diagnostics Sales

Forecast by Market Segment

U.S.A.

CMV Test Volume and Diagnostics Sales Forecast by Market

Segment

U.S.A.

E. Coli Test Volume and Diagnostics Sales Forecast by Market

Segment

U.S.A.

Echovirus Test Volume and Diagnostics Sales Forecast by Market

Segment

U.S.A.

Encephalitis Test Volume and Diagnostics Sales Forecast by

Market

Segment

U.S.A.

Enterovirus Test Volume and Diagnostics Sales Forecast by

Market

Segment

U.S.A.

EBV Test Volume and Diagnostics Sales Forecast by Market

Segment

U.S.A.

Giardia Test Volume and Diagnostics Sales Forecast by Market

Segment

U.S.A.

Gonorrhea Test Volume and Diagnostics Sales Forecast by

Market Segment

U.S.A.

Granuloma Inguinale Test Volume and Diagnostics

Sales Forecast by Market Segment

U.S.A.Hantavirus Test Volume and Diagnostics Sales Forecast byMarket SegmentU.S.A.Helicobacter Pylori Test Volume and DiagnosticsSales Forecast by Market SegmentU.S.A.HAV NAT Test Volume and Diagnostics Sales Forecast by MarketSegmentU.S.A.HBV NAT Test Volume and Diagnostics Sales Forecast by MarketSegmentU.S.A.HbsAg Test Volume and Diagnostics Sales Forecast by MarketSegmentU.S.A.Hepatitis C Test Volume and Diagnostics Sales Forecast byMarket SegmentU.S.A.Anti-HBC Test Volume and Diagnostics Sales Forecast byMarket SegmentU.S.A.Anti-HBS Test Volume and Diagnostics Sales Forecast byMarket SegmentU.S.A.Anti-HAV Test Volume and Diagnostics Sales Forecast byMarket SegmentU.S.A.Hepatitis Delta Test Volume and Diagnostics SalesForecast by Market Segment

U.S.A.

HBcAg Test Volume and Diagnostics Sales Forecast by

Market Segment

U.S.A.

HBeAg Test Volume and Diagnostics Sales Forecast by Market

Segment

U.S.A.

ALT/SGPT Test Volume and Diagnostics Sales Forecast by

Market Segment

U.S.A.

Herpes Simplex I and II Test Volume and Diagnostics

Sales Forecast by Market Segment

U.S.A.

Herpes Type VI Test Volume and Diagnostics Sales

Forecast by Market Segment

U.S.A.

Influenza Test Volume and Diagnostics Sales Forecast by

Market Segment

U.S.A.

Legionella Test Volume and Diagnostics Sales Forecast by

Market Segment

U.S.A.

Lyme Disease Test Volume and Diagnostics Sales Forecast by

Market Segment

U.S.A.

Lymphogranuloma Test Volume and Diagnostics Sales Forecast by

Market Segment

U.S.A.

Malaria Test Volume and Diagnostics Sales Forecast by Market

Segment

U.S.A.Measles Test Volume and Diagnostics Sales Forecast byMarket SegmentU.S.A.Meningitis Test Volume and Diagnostics Sales Forecast byMarketSegmentU.S.A.Microsporidium Test Volume and Diagnostics Sales Forecast byMarket SegmentU.S.A.Mononucleosis Test Volume and Diagnostics Sales Forecast byMarket SegmentU.S.A.Mumps Test Volume and Diagnostics Sales Forecast by MarketSegmentU.S.A.Mycoplasma Test Volume and Diagnostics Sales Forecast byMarket SegmentU.S.A.Papilloma Virus Test Volume and Diagnostics SalesForecast by Market SegmentU.s.a.Parvovirus Test Volume and Diagnostics Sales Forecast byMarket SegmentU.S.A.Pneumonia Test Volume and Diagnostics Sales Forecast byMarket SegmentU.S.A.Polyomaviruses Test Volume and Diagnostics Sales Forecast byMarket Segment

U.S.A.

Pseudomonas Test Volume and Diagnostics Sales Forecast by

Market Segment

U.S.A.

Rabies

Test Volume and Diagnostics Sales Forecast by Market Segment

U.S.A.

RSV

Test Volume and Diagnostics Sales Forecast by Market Segment

U.S.A.

Rhinovirus Test Volume and Diagnostics Sales Forecast by

Market

Segment

U.S.A.

Rotavirus Test Volume and Diagnostics Sales Forecast by Market

Segment

U.S.A.

Rubella Test Volume and Diagnostics Sales Forecast by Market

Segment

U.S.A.

Salmonella Test Volume and Diagnostics Sales Forecast by

Market

Segment

U.S.A.

Septicemia Test Volume and Diagnostics Sales Forecast by

Market

Segment

U.S.A.

Shigella Test Volume and Diagnostics Sales Forecast by Market

Segment

U.S.A.Staphylococci Test Volume and Diagnostics Sales Forecast byMarket SegmentU.S.A.Streptococci Test Volume and Diagnostics Sales Forecast byMarket SegmentU.S.A.Syphilis Test Volume and Diagnostics Sales Forecast byMarket SegmentU.S.A.Toxoplasmosis Test Volume and Diagnostics Sales Forecast byMarket SegmentU.S.A.Trichomonas Test Volume and Diagnostics Sales Forecast byMarket SegmentU.S.A.Tuberculosis Test Volume and Diagnostics Sales Forecast byMarket SegmentU.S.A.Vibrio Test Volume and Diagnostics Sales Forecast by MarketSegmentU.S.A.West Nile Test Volume and Diagnostics Sales Forecast by MarketSegmentU.S.A.Yersinia Test Volume and Diagnostics Sales Forecast byMarket SegmentU.S.A.AIDS Testing Market Diagnostics Sales by MajorSupplier

U.S.A.

Adenovirus Testing Market Diagnostics Sales by

Major Supplier

U.S.A.

Campylobacter Testing Market Diagnostics Sales by

Major Supplier

U.S.A.

Candida Testing Market Diagnostics Sales by Major

Supplier

U.S.A.

Chancroid Testing Market Diagnostics Sales by Major

Supplier

U.S.A.

Chlamydia Testing Market Diagnostics Sales by Major

Supplier

U.S.A.

CMV Testing Market Diagnostics Sales by Major

Supplier

U.S.A.

Cryptosporidium Testing Market Diagnostics Sales by Major

Supplier

U.S.A.

Echovirus Testing Market Diagnostics Sales by Major

Supplier

U.S.A.

Enterovirus Testing Market Diagnostics Sales by

Major Supplier

U.S.A.

EBV Testing Market Diagnostics Sales by Major

Supplier

U.S.A.Giardia Testing Market Diagnostics Sales by MajorSupplierU.S.A.Gonorrhea Testing Market Diagnostics Sales by MajorSupplierU.S.A.Helicobacter Pylori Testing Market Diagnostics Sales by MajorSupplierU.S.A.Hepatitis Testing Market Diagnostics Sales by MajorSupplierU.S.A.Hepatitis C Testing Market Diagnostics Sales byMajor SupplierU.S.A.Herpes Testing Market Diagnostics Sales by MajorSupplierU.S.A.Influenza Testing Market Diagnostics Sales by MajorSupplierU.S.A.Legionella Testing Market Diagnostics Sales byMajor SupplierU.S.A.Lyme Disease Testing Market Diagnostics Sales byMajor SupplierU.S.A.Measles Testing Market Diagnostics Sales byMajor Supplier

U.S.A.

Meningitis Testing Market Diagnostics Sales by Major

Supplier

U.S.A.

Mononucleosis Testing Market Diagnostics Sales by

Major Supplier

U.S.A.

Mumps Testing Market Diagnostics Sales by Major

Supplier

U.S.A.

Mycoplasma Testing Market Diagnostics Sales by

Major Supplier

U.S.A.

Pneumonia Testing Market Diagnostics Sales by Major

Supplier

U.S.A.

Rabies Testing Market Diagnostics Sales by Major

Supplier

U.S.A.

RSV Testing Market Diagnostics Sales by Major

Supplier

U.S.A.

Rotavirus Testing Market Diagnostics Sales by Major

Supplier

U.S.A.

Rubella Testing Market Diagnostics Sales by Major

Supplier

U.S.A.

Salmonella Testing Market Diagnostics Sales by

Major Supplier

U.S.A.Septicemia Testing Market Diagnostics Sales byMajor SupplierU.S.A.Shigella Testing Market Diagnostics Sales by MajorSupplierU.S.A.Streptococci Testing Market Diagnostics Sales byMajor SupplierU.S.A.Syphilis Testing Market Diagnostics Sales by MajorSupplierU.S.A.Toxoplasmosis Testing Market Diagnostics Sales byMajor Supplier

To order this report:In Vitro Diagnostic Industry: Future US Microbiology Testing Market Outlook

More  

Market Research Report

Check our  

Industry Analysis and Insights

CONTACT
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

Read more:
Future US Microbiology Testing Market Outlook

Home Care Assistance Launches AgingAdult.org

AgingAdult.org provides people curious to learn more about healthy longevity with scientifically based lifestyle tips and advice to help inspire them to live healthier and happier lives at any age

Palo Alto, CA (PRWEB) February 13, 2012

Home Care Assistance, the leading provider of in-home care for seniors, is proud to announce the launch of AgingAdult.org. Initially conceptualized as a resource for aging adults looking to learn more about healthy longevity, initial response to the website has come from a wide spectrum of age groups. By filling out the form on the website, individuals will automatically receive the downloadable version of the renowned aging book Happy to 102, a popular book that provides practical lifestyle tips and advice for not only living longer, but living well longer. This is a valuable resource for anyone interesting in healthy aging. The book is based on years of research following the inhabitants of the island of Okinawa in Japan, referred to as the best place for aging given that it has the highest life expectancy for men and women over the age of 65, and distills it into accessible lifestyle advice. In addition to being a highly engaging and enjoyable read, Happy to 102 provides guidance on the lifestyle behaviors and psychology that promote quality of life and aging well.

“AgingAdult.org is one of many consumer educational initiatives we are developing to provide education around the types of topics that our clients and the community have voiced an interest in learning more about,” said Kathryn Zakskorn, Public Relations and Marketing Manager of Home Care Assistance. “With an aging population comes an increased desire to learn about healthy longevity and we are excited to be able to provide this information in an accessible way.”

Whether you are a young adult looking to expand your knowledge of healthy longevity, a family caregiver wanting to learn more about aging well so that you can share that information with your loved one or an aging adult hoping to find practical advice to help you make the optimal lifestyle choices to ensure healthy nutrition and exercise, an active mind and a sense of calmness and purpose, AgingAdult.org will be an extremely valuable resource.

“It is profoundly liberating to let go of the belief that your life expectancy is predetermined solely based on genetic factors and instead embrace the view that you are in charge of your own longevity journey through the healthy lifestyle choices you make,” said Shadi Gholizadeh, Business Operations Manager of Home Care Assistance. “Our mission at Home Care Assistance is to change the way the world ages; we believe in empowering people to be proactive and informed when it comes to their health.”

For more information about Home Care Assistance please visit http://www.HomeCareAssistance.com or call 1-866-454-8346.

ABOUT HOME CARE ASSISTANCE

Home Care Assistance is the leading provider of home care for seniors across the United States and Canada. Our mission is to change the way the world ages. We provide older adults with quality care that enables them to live happier, healthier lives at home. Our services are distinguished by the caliber of our caregivers, the responsiveness of our staff and our expertise in Live-In care. We embrace a positive, balanced approach to aging centered on the evolving needs of older adults. A 2012 Franchise500® Company, Home Care Assistance has received numerous industry awards including Entrepreneur’s Fastest-Growing Franchises and Franchise Business Review’s Top 50. For more information about Home Care Assistance, our services and franchise opportunities, visit homecareassistance.com or franchise.homecareassistance.com.

###

Kathryn Zakskorn
Home Care Assistance
650-462-9501
Email Information

View post:
Home Care Assistance Launches AgingAdult.org

Prudential Retirement reinsures retirement benefits through transaction with Rothesay Life

NEWARK, N.J.--(BUSINESS WIRE)--

Prudential Retirement, a business unit of Prudential Financial, Inc. (NYSE: PRU - News), today announced its first longevity reinsurance transaction of 2012.

Under the terms of the transaction, Prudential Retirement will provide reinsurance of longevity risk to Rothesay Life, a wholly-owned subsidiary of The Goldman Sachs Group, Inc. The transaction initially covers pension liability values of GBP 423 million, approximately equal to $665 million U.S. dollars.

The reinsurance secures the retirement benefits of almost 20,000 members of the Uniq Plc Pension Scheme, who are insured by Rothesay Life. The reinsurance transaction is particularly significant as it covers the risks of all life annuities held by plan participants, regardless of age or retirement status, and over half the plan participants reinsured have yet to reach retirement.

“We are happy to partner with Rothesay on another innovative Pension Risk Transfer transaction that helps to secure the retirement benefits of Uniq’s members,” said Amy Kessler, senior vice president and head of Prudential’s Longevity Reinsurance business.

“Rothesay Life is pleased to continue its partnership with Prudential,” said Addy Loudiadis, chief executive officer, Rothesay Life. “This latest transaction demonstrates how we can work together to complete an important transaction.”

Reinsurance contracts are issued by Prudential Retirement Insurance and Annuity Company (PRIAC), Hartford, CT 06103. PRIAC is not a U.K. Financial Services Authority (FSA) authorized insurer and does not conduct business in the United Kingdom or provide direct insurance to any individual or entity therein. Prudential Financial, Inc. of the United States is not affiliated with Prudential plc, which is headquartered in the United Kingdom.

Rothesay Life is an insurance company established in the U.K. as a wholly-owned subsidiary of The Goldman Sachs Group, Inc., a bank holding company and leading global investment banking, securities and investment management firm. Rothesay Life provides annuity and other longevity products to corporate defined benefit pension plans, tailored to meet the specific needs of corporate sponsors, trustees and pension plan members. Rothesay Life is authorized and regulated by the U.K.’s Financial Services Authority.

Prudential Retirement delivers retirement plan solutions for public, private, and non-profit organizations. Services include state-of-the-art record keeping, administrative services, investment management, comprehensive employee investment education and communications, and trustee services. With over 85 years of retirement experience, Prudential Retirement helps meet the needs of nearly 3.6 million participants and annuitants. Prudential Retirement has $229.5 billion in retirement account values as of December 31, 2011.

Prudential Financial, Inc. (NYSE: PRU - News), a financial services leader with approximately $901 billion of assets under management as of December 31, 2011, has operations in the United States, Asia, Europe, and Latin America. Prudential’s diverse and talented employees are committed to helping individual and institutional customers grow and protect their wealth through a variety of products and services, including life insurance, annuities, retirement-related services, mutual funds and investment management. In the U.S., Prudential’s iconic Rock symbol has stood for strength, stability, expertise and innovation for more than a century. For more information, please visit http://www.news.prudential.com/.

0218717-00001-00

See the original post:
Prudential Retirement reinsures retirement benefits through transaction with Rothesay Life

DNA barcoding of parasitic worms: Is it kosher?

Public release date: 14-Feb-2012
[ | E-mail | Share ]

Contact: Kendra Snyder
ksnyder@amnh.org
212-496-3419
American Museum of Natural History

When rabbis from the Orthodox Union started finding worms in cans of sardines and capelin eggs, they turned to scientists at the American Museum of Natural History to answer a culturally significant dietary question: could these foods still be considered kosher?

Using a technique called "DNA barcoding" at the Museum's Sackler Institute for Comparative Genomics, researchers identified the species and life cycles of the parasitic worms to determine whether the food's preparation violated Jewish dietary laws. The results, which were recently published online in the Journal of Parasitology, show that although the food contains a handful of species of roundworms, it is kosher.

"About 75 percent of all pre-packaged food has a kosher certification," said Mark Siddall, a curator in the Museum's Division of Invertebrate Zoology. "Many people, not just those in the Jewish community, look for this certification as a symbol of quality assurance in food preparation. If you're a food provider and you lose that certification, you're going to take a large hit."

The study began last March, when rabbinical experts from the Orthodox Union, the largest organization that certifies food products for the Jewish community, brought a variety of kosher-certified sardines and capelin eggs to the Museum. Their concern: the presence of the worms might be a sign that intestinal contents were allowed to mix with sardine meat or preserved capelin eggs during food preparation. If that were the case, kosher certification would be compromised.

The key to determining whether the canned food was improperly handled is in the worms' life cycles, Siddall said. "Some species of worms live in the muscles of fish when they're in the larval stage," he said. "Other species live in the fish's intestines when they're adults. We already know the life cycles for these parasites, so all we have to do is figure out what species were present in the canned food."

To do this, researchers used genetic barcoding, a technology based on a relatively short region of a gene in the mitochondrion, an energy-producing structure located outside of the cell's nucleus, that allows researchers to efficiently identify the species from which a piece of meat?or even a leather handbag?came from.

Work by Museum scientists has long included and promoted this technique, which has identified the presence of endangered whales in Asian markets, documented fraud in the labeling of tuna, and determined the species of animals on sale in African bushmeat markets. In this case, the scientists identified a handful of different nematode species, none of which are known to live in the guts of fish during their lifecycles?therefore, there's no evidence of intestinal worms co-mingling with the fish meat or eggs.

As a result, the Orthodox Union issued a decision that the food remains kosher.

"To our knowledge, this is the first application of DNA barcoding to an obviously cultural concern," said Sebastian Kvist, one of the paper's authors and a student in the Museum's Richard Gilder Graduate School. "This paper really exemplifies what science is all about?helping people."

###

Other authors include Anna Phillips, from the University of Connecticut, and Alejandro Oceguera-Figuero, from the National Autonomous University of Mexico.

Funding for the Museum's DNA Barcoding Initiative is provided by the Alfred P. Sloan Foundation and the Richard Lounsbery Foundation.

[ | E-mail | Share ]

 

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

See the original post here:
DNA barcoding of parasitic worms: Is it kosher?

Posted in DNA

Industry-Standard Covaris DNA Shearing Performance for Every Laboratory – Large or Small

WOBURN, Mass., Feb. 14, 2012 /PRNewswire/ -- The M220 Ultrasonicator is the newest DNA shearing system from Covaris.

The M220 is designed for Next-Gen sequencing applications. Using highly controlled AFA™ (Adaptive Focused Acoustics) technology, the M220 reproducibly shears DNA into random fragments ranging from 100bp to 1.5kb.

Compact, cost effective, and easy-to-use, the M220 is the ideal shearing system for MiSeq™ and PGM™ users. The M220 includes integrated cooling, eliminating the extra cost and space required for an external chiller, as well as reducing startup time to just 10 minutes. Using Covaris' microTUBE and miniTUBE consumables and lab-proven protocols, the M220 provides the high quality shearing results researchers have come to expect from Covaris.

The M220 provides the same performance benefits as the market leading S-series and E-series systems from Covaris including, precise energy control for user-selectable DNA fragment lengths, an isothermal process eliminating heat-induced molecular damage, closed vessels for highest sample recovery, and a non-contact process that eliminates cross contamination and clean-up. The M220 was recently released at SLAS and will be presented with performance data at AGBT 2012.

Covaris offers a complete range of DNA shearing products for all Next-Gen sequencing needs. For more information about the M220 Ultrasonicator please visit http://www.covarisinc.com.

About Covaris, Inc.

Covaris, Inc. provides advanced sample preparation systems for life and analytical science. Our sample prep technologies support a wide variety of applications including Next-Generation DNA sequencing, ChIP, proteomics, and compound management. Our patented Adaptive Focused Acoustic (AFA) technology enables a high energy density to bring unsurpassed speed and efficiency to biological and chemical sample preparation. The AFA process, based on shock wave physics, delivers controlled, precise, and accurate energy to biological and chemical samples.

Read this article:
Industry-Standard Covaris DNA Shearing Performance for Every Laboratory - Large or Small

Posted in DNA

CustoMerQ Botanical DNA Ink to Protect Sekiaji and Sekisaba Fish in Japan

STONY BROOK, NY--(Marketwire -02/14/12)- A botanical DNA ink "CustoMerQ" developed by Nissha Printing Co., Ltd. (hereafter, Nissha) in conjunction with Applied DNA Sciences (OTC.BB: APDN.OB - News), has been adopted by the Saganoseki Branch of the Oita Fisheries Co-operative Association. It will be used at hygienically controlled facilities beginning in April 2012. These facilities will have an integrated processing line from unloading to shipping for products including "Sekiaji" horse mackerel and "Sekisaba" common mackerel. CustoMerQ DNA ink will be used to print the shipping date and shipping number on the brand label that is attached to the product.

CustoMerQ DNA Ink will help prevent counterfeiting of the label and will preserve the brand name for the marine products caught in the Saganoseki area. It will also be possible to match the shipping number that has been printed with information on a website, so that the end consumer can check the shipping information for the product online.

DNA as the Ironclad Anti-Counterfeiting Solution

Nissha identified Applied DNA technology as the most ironclad product authentication solution, stating its determination that DNA, as a trusted forensic form of authentication in courts around the world, provides the highest security for high value food and other products.

The new CustoMerQ DNA Ink system, developed by Nissha in conjunction with APDN, can be used in a wide variety of products such as food packaging, with its forgery-proof, high security layer. The anti-counterfeiting CustoMerQ DNA ink on food labels can be instantly verified as genuine in the field, using a special handheld detector to identify the anti-counterfeiting ink. This could happen at the point of sale, or at any point along the supply chain. As is typical of APDN botanical DNA markers, a second, forensic level of authentication is also available by sending the suspect product to a secure, product authentication lab.

Branded foods from particular and often well-known waters off Japan, and sometimes preserved with traditional, labor-intensive methods, are becoming popular, profitable, and necessary in Asia. For example, sushi bars have become ever-more discriminating, while ocean contamination and other issues beset the fishing industry. Counterfeiters and diverters have moved in with force, selling common foods as the high-value brand, destroying markets and reputation of the real item.

Nissha, listed on the Tokyo Stock Exchange (Company Code: 7915), has a market capitalization of ¥40 billion (or approximately $500 million US dollars). Headquartered in Kyoto, Japan, Nissha is a globally networked company with over 4,000 employees (consolidated), 11 locations in Japan and 27 bases located throughout Asia, North America and Europe.

About APDN

APDN sells patented DNA security solutions to protect products, brands and intellectual property from counterfeiting and diversion. SigNature DNA is a botanical mark used to authenticate products in a unique manner that essentially cannot be copied. Our mark provides a forensic chain of evidence that can be used to prosecute perpetrators. To learn more, go to http://www.adnas.com where APDN routinely posts all press releases.

The statements made by APDN may be forward-looking in nature. Forward-looking statements describe APDN's future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN's SEC reports and filings, including our Annual Report on Form 10-K, filed on December 8, 2011 and our subsequent quarterly reports on Form 10-Q. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events.

View original post here:
CustoMerQ Botanical DNA Ink to Protect Sekiaji and Sekisaba Fish in Japan

Posted in DNA

DNAnexus Announces Strategic Alliances to Drive the Advancement of DNA-Based Medicine

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--

DNAnexus, a DNA data management and analysis platform, today announced agreements with leading institutions – Geisinger Health System (GHS) and the University of California, San Francisco (UCSF) – to develop clinically relevant workflows to provide new insights into the use of DNA sequencing in medicine.

As part of these relationships, key laboratories within GHS and UCSF will leverage DNAnexus’ cloud-based software platform to upload, store and analyze DNA sequencing data. In conjunction with the Geisinger Clinical Program for Whole Genome Sequencing (WGS), GHS will have access to DNAnexus’ genomic data management capabilities including visualization, analysis and storage. The healthcare organization, in turn, will provide strategic counsel around the use of WGS data in clinical settings, and the extension of DNAnexus’ capabilities to further support such use.

“At Geisinger, providing the best personalized healthcare has always been our mission, and key to that is the ability to collect and manage valuable medical information like electronic health records, blood samples and DNA sequencing data,” said Dr. David Ledbetter, chief scientific officer, Geisinger Health System. “As whole genome sequencing becomes more affordable and accessible, we are eager to work with DNAnexus to find ways to manage this critical data asset and better leverage it within the clinical workflow.”

“In the past few years, the pace of development in DNA sequencing technology has been astounding, doubling in capacity even faster than the classic Moore’s law of computing,” said David J. Erle, MD, UCSF professor of medicine and director of the Functional Genomics Core Facility in the UCSF Sandler Center for Basic Research in Asthma. “That has a huge impact on our ability to understand both health and disease, but it also poses a formidable challenge. In many cases, scientists are now limited more by their ability to store and analyze the data than they are by their ability to generate it.”

These new strategic agreements further DNAnexus’ goal of delivering the definitive big data system for DNA to both the commercial and academic communities. A cloud-based solution, DNAnexus provides instant online genomics data centers for sequencing operations, research organizations, and clinical applications of virtually any size without any required hardware investment on the part of the customer. Founded in 2009, DNAnexus is supported by leading investors including Google Ventures and TPG Biotech.

“We are at the beginning of a genomics-driven revolution in healthcare, and DNAnexus is focused on providing a unified technology platform that makes managing, storing, and analyzing sequencing data easier for everyone,” said Andreas Sundquist, PhD co-founder and CEO of DNAnexus. “By partnering with highly respected healthcare and research institutions like Geisinger and UCSF, we will be able to learn from clinical experts and build an even more innovative solution that will enable research, medical and biotech communities to unlock the full potential of DNA data.”

About DNAnexus

DNAnexus is powering the genomics revolution. The company’s mission is to unlock the potential of DNA-based medicine and biotechnology with a scalable and collaborative data technology platform. DNAnexus’ cloud-based platform is an instant online genomics data center that provides secure and efficient management, storage, and analysis of DNA data. For more information please visit https://dnanexus.com.

About Geisinger Health Care System

Geisinger is an integrated health services organization widely recognized for its innovative use of the electronic health record, and the development and implementation of innovative care models including ProvenHealth Navigator, an advanced medical home model, and ProvenCare program. The system serves more than 2.6 million residents throughout 44 counties in central and northeastern Pennsylvania. For more information, visit http://geisinger.org. Follow the latest Geisinger news and more at Twitter and Facebook.

About University of California, San Francisco

UCSF is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care.

UC Disclaimer

The information stated above was prepared by DNAnexus and reflects solely the opinion of the corporation. Nothing in this statement shall be construed to imply any support or endorsement of DNAnexus, or any of its products, by The Regents of the University of California, its officers, agents and employees.

More:
DNAnexus Announces Strategic Alliances to Drive the Advancement of DNA-Based Medicine

Posted in DNA

DNA Seattle Adds Two Seattle Ad Veterans as Associate Creative Directors

SEATTLE--(BUSINESS WIRE)--

DNA Seattle, an independent full-service agency with expertise in brand strategy, advertising, digital strategy and media, announced today that it has added to its creative talent base with the hiring of Pete Hughes and Lianne Onart.

As associate creative directors, Hughes and Onart are responsible for inspiring creativity, creating powerful brand campaigns and helping guide the creative success of the agency.

Both come to DNA Seattle with years of agency experience working on regional, national and international brands such as Dodge, Jeep, Chrysler, HP, Microsoft, T-Mobile, Kraft, UW Athletics, UW Medicine, Westin Hotels and Resorts, Ann Taylor, Gortex and Target.

“I’m thrilled to have Pete and Lianne join the company. We all know each other pretty well from years of working in the Seattle ad world. We have similar philosophies and working styles, they have tons of talent, and last, but not least, they’re just a lot of fun to be around. They are a great addition both for our clients and for our growing team here at DNA,” said Dan Gross, principal and executive creative director at DNA Seattle.

Pete Hughes brings more than sixteen years of experience as a copywriter and creative director at BBDO, FCB, Cole and Weber, and Publicis. His work has received recognition from the British D&AD, Clio, Cannes, Archive, and Seattle Show. Pete has a bachelor’s degree in communications from Washington State University. He also attended the School of Visual Concepts.

"DNA has a unique combination of talent and experience, and a solid track record of producing phenomenal creative and business results for their clients. I look forward to helping DNA attract the best talent available, doing great work, making our clients famous, and having fun,” said Hughes.

Prior to joining DNA, Lianne Onart created compelling campaigns at Foote Cone & Belding, Hydrogen and Cole & Weber. Additionally, she started her own company that specialized in marketing to women, creating brand campaigns for the first women-specific outdoor gear for Gortex, Sidi Cycling Shoes and Sierra Designs. Onart regularly advises Seattle Community College graduates and has taught advertising and design classes at The School of Visual Concepts. She also works with Fred Hutchinson Cancer Research Center and The Multiple Sclerosis Society (Greater Washington Chapter) designing marketing materials.

“I was attracted to DNA because of their great creative work, the good people and of course, their great office space! Alan, Dan and Chris are very passionate about the work and the agency culture. I really feel like I can make a difference here to inspire and ignite my peers to do interesting and unusual work for that creates die-hard brand loyalists for our clients,” said Onart.

About DNA

Founded in 1998, DNA is a full-service marketing communications agency based in Seattle, Washington. The agency provides services in brand strategy, advertising, interactive and design. As one of the fastest growing agencies on the West Coast, DNA has a talent and passion for transforming brands—and helping their client partners win unreasoning loyalty from their customers and prospects in the process. Some of DNA’s clients include: PEMCO Insurance, BECU, The Avon Foundation, F5, Executive Travel Magazine, GlobalScholar and University of Washington. Visit DNA on the Web at http://www.dnaseattle.com, on Twitter at @dnaseattle and on Facebook.

Read this article:
DNA Seattle Adds Two Seattle Ad Veterans as Associate Creative Directors

Posted in DNA

Nabsys to Present DNA Sequence Data from Solid-State Nanodetectors at the Annual Advances in Genome Biology and …

PROVIDENCE, R.I., Feb. 14, 2012 /PRNewswire/ -- Nabsys, Inc., a life sciences company pioneering development of solid-state single-molecule positional sequencing technology, today announced that data demonstrating the first direct electronic re-sequencing and mapping of DNA will be presented at the annual Advances in Genome Biology and Technology (AGBT) meeting, February 15 to 18, on Marco Island, Fla., and the Omics and Personalized Medicine Conference at the European Molecular Biology Laboratory (EMBL), February 16 to 18,  in Heidelberg, Germany.   

Nabsys' positional sequencing platform uniquely reveals information about both the identity and location of DNA sequences through direct electrical detection of probes bound to single molecules that may be as large as hundreds of kilobases in length. Depending on how the methodology is deployed, the platform can be used to analyze the full size scale of DNA variation, including single-base resolved sequence, large scale genomic structural variants, chromosomal aneuploidies, and any combination of the above.

"Significant improvements have been made over the past few years in the speed, throughput and cost of generating DNA sequence information, creating great enthusiasm for applying sequencing technology in the clinic," said Barrett Bready, M.D., chief executive officer of Nabsys. "While these advances have been impressive and important, many applications of sequence data – in medicine as well as in basic biological research and agriculture – require similar levels of improvement in data accuracy, information content, reduced data and computational burden, and simplified workflow.  The data we are presenting at AGBT and EMBL demonstrate what is possible with purely solid-state detection.  These data provide insights into how the Nabsys positional sequencing platform, once scaled, has the potential to set new performance standards and open new markets for DNA sequence analysis."

In contrast to other approaches referred to as "nanopore sequencing," positional sequencing does not attempt to discriminate individual nucleotide bases passing through an electrical detector.  Instead, the Nabsys approach involves hybridization of short oligonucleotide probes to very long DNA templates, passage of probe-bound templates through solid-state nanodetectors, and electronic detection of the locations of hybridized probes.  By combining information on the positions of many such probes, it is possible to create detailed genomic maps with sparse probe coverage, or true de novo sequences of large genomes with dense probe coverage. 

Positional sequencing does not require slowing down DNA translocation rates through nanodetectors.  Information can thus be generated very rapidly over unprecedented length scales with a method that is inherently targeted, quantitative, and involves a simple workflow.  The use of solid-state nanodetectors provides the basis for a platform that is highly scalable, with the potential for enormous advances in throughput, dramatically reduced data burden, and high volume manufacturing.

Data to be presented will demonstrate that Nabsys' nanodetector design and DNA preparation techniques enable:

Analysis of single DNA molecules up to 50kb in length Mapping of probes with precision that greatly exceeds the diffraction limit of light Re-sequencing of targeted regions without a capture or enrichment step Analysis of genome structural variants

About Nabsys

Nabsys is dedicated to enabling advances in life sciences and healthcare through strategic deployment of a novel positional sequencing platform with broad applicability for DNA analysis. The Nabsys platform uses solid-state nanodetectors to analyze single DNA molecules, revealing both location and identity of DNA sequences over long distances. The system is designed to set new standards for accuracy, speed and scalability, offering compelling advantages for the analysis of genome structural variation, genome mapping, and both targeted and whole genome sequencing. Nabsys was the first company to receive a "$1000 Genome" award from the National Human Genome Research Institute of the National Institutes of Health for an electronic approach to sequencing DNA. For more information about Nabsys, please visit http://www.Nabsys.com.

Company Contact:
Barrett Bready, M.D.
President, Chief Executive Officer and Director
Nabsys, Inc.
401-276-9100  Ext. 200
bready@nabsys.com

Media Contact:
Robert Flamm, Ph.D. or Martina Schwarzkopf, Ph.D.
Russo Partners
212-845-4226
212-845-4292
Robert.flamm@russopartnersllc.com 
Martina.schwarzkopf@russopartnersllc.com

Read the rest here:
Nabsys to Present DNA Sequence Data from Solid-State Nanodetectors at the Annual Advances in Genome Biology and ...

UK to use former Northside Branch of Lexington Public Library for outreach, research

By Mary Chellis Austin

Come August, undergraduate biology students will share the old Northside Branch of the Lexington Public Library, located on Russell Clave Road, with a UK outreach program.

The P-12 Math and Science outreach unit of the Partnership Institute for Math and Science Education Reform provides outreach groups and training for administrators and teachers in the areas of math and science.

No permanent residence exists for the unit of PIMSER.

“We used to use local churches. We’ve used a lot of hotels,” said Kim Zeidler-Watters, director of the program.

For those who travel far, “the space allows for easy access,” Zeidler-Watters said. “Many come from western or eastern Kentucky for the outreach program.”

Parking will be available, and everything is on one level so educators won’t have to haul materials up stairs. It is also close to the interstate, so campus traffic can be avoided.

Zeidler-Watters said she hopes to eventually have an expansion on the back for a larger training space with a capacity of 70-150.

Bought by the university in 2008, the Northside building is now part of the ecological research facility. It sits aside a 55-acre field, home to animals that aid in ecological research, UK Provost Kumble Subbaswamy said.

For the biology department, “it was natural to acquire the building,” Subbaswamy said.

According to their website, the biology department will have a “30-seat teaching laboratory with prep room, office and computer labs, and access to shared classroom space in this building.”

Plans for the renovation began last week and include the restructuring of internal walls and storage spaces.

Subbaswamy said it will cost $2.3 million, but not all of the money is coming from the university.

For its 20 anniversary last year, Lexmark gave $1 million toward the renovation.

“We’re very excited about our role in helping the university transform the former Northside Library into a resource center for science, technology, engineering and math education,” Sheri Evans Depp, director of Talent Management for Lexmark, said in an email to the Kernel. “Our goal is to encourage more students to pursue careers in math and science and help fuel growth and innovation in our community.”

Not only do biology and education students benefit, but the building is also an opportunity for the “pipeline of high school students,” Subbaswamy said. “It’s a win-win-win situation.”

Originally posted here:
UK to use former Northside Branch of Lexington Public Library for outreach, research

Avesthagen Signs MOU with CosmosID™ for Improving Diagnosis and Management of Tuberculosis

BANGALORE, India--(BUSINESS WIRE)--

Avesthagen Limited – India’s leading systems biology biotechnology company, has signed a MOU with CosmosID™, a U.S. based company for collaborating to correctly diagnose and therapeutically manage Tuberculosis treatment.

Tuberculosis or TB is a tropical disease caused by Mycobacterium tuberculosis, a bacterium. Bacteria, in general and M. tuberculosis, in particular, can mutate into various forms called strains. Strains may be infectious or non-infectious and may vary in their disease causing abilities or virulence. Traditionally, TB patients are treated with antibiotics without an analysis of the strain involved. This generic approach may cause problems as the strain involved may not be virulent or may have developed resistance to a particular antibiotic.

Avesthagen and CosmosID will pool their expertise to identify the particular TB strain and thereby support proper treatment. The collaboration is expected to result in a new method for developing diagnostic kits for rapid screening of patient samples.

According to Dr. Villoo Morawala-Patell, Founder & CMD of Avesthagen Limited, “Tuberculosis is a serious infectious disease and the efficacy of its treatment lies in accurate and rapid identification of the TB strains. Avesthagen has been working on TB for some time and has developed a genomic data pool. In CosmosID we have found a leader and strong partner, developing rapid pathogen identification methods, MetaSeq™ Genomics, to facilitate more precise diagnostic screening of infectious disease in a single, rapid, and accurate test. The collaboration will help in improving the healthcare in developing and lesser developed countries where it is needed the most.”

Dr. Rita Colwell, Founder and Chairman of CosmosID said, "We are proud to be associated with Avesthagen on this important project. Our collaboration will provide significant benefits for TB patients worldwide and demonstrates a new paradigm for medical diagnostic screening of infectious disease.”

About Avesthagen Limited:

Avesthagen is India’s leading integrated systems biology platform company that focuses on achieving convergence of food, pharma and population genetics leading to predictive preventive and personalized healthcare. Avesthagen partners include multiple top 10 global companies in each of its fields of research. Since its inception Avesthagen has grown into one of India’s leading healthcare biotech companies. Avesthagen has developed clinically validated botanical bioactives and has a strong pipeline of bio-similars.

http://www.avesthagen.com Contact anilram@avesthagen.com

About CosmosID™, Inc.:

CosmosID™, Inc. is a privately owned company based in College Park, MD that provides pathogen diagnostic software solutions for rapid identification of pathogens, antibiotic resistant determinants, and virulence factors. The Company works with customers in the fields of microbial detection, product safety, biosecurity, bioforensics, and medical diagnostics. Based on NextGen sequencing, software, and reference databases, it develops applications to identify environmental microbial hazards, biothreat agents that endanger public health, and pathogens that cause infectious disease.

For further information, contact Bob Evans, bob.evans@cosmosid.net or http://www.cosmosid.com.

Read the original post:
Avesthagen Signs MOU with CosmosID™ for Improving Diagnosis and Management of Tuberculosis

How To Genetically Modify Yogurt

Tuur van Balen gives a provocative how-to presentation at the Next Nature Power Show, showing how to use the Synthetic Biology Parts Registry to engineer yogurt bacteria to produce prozac:

Van Balen is a designer whose work explores the boundary between art and science in synthetic biology. From his website:

Tuur Van Balen (Belgium, 1981) uses design to explore the political implications of emerging technologies. Through designing and experimenting with new interactions, he constructs thought-provoking new realities. Both the process of creating these objects, interventions and narratives as the resulting physical presence aim to confuse, question and confront different publics with the possible (and impossible) roles of technologies in our everyday lives.

I couldn’t find BioBricks in the Parts Registry for the production of prozac, but you can learn more about engineering the yogurt bacteria Lactobacillus to produce new colors and flavors from the 2007 Edinburgh iGEM team and making your own incubator and other lab supplies from the 2010 ArtScience Bangalore iGEM team. More about Van Balen’s other projects can be found on his website, including Pigeon d’Or, which imagines using BioBricks that produce grease-digesting lipases to engineer bacteria that live in the pigeon digestive tract, turning this urban pest into a helpful city cleaning system.

While getting DNA into a (well-studied, culturable) bacterial cell might be easier than you think, the task of designing and optimizing a functional, useful, and safe gene system is a lot more complicated, providing both the excitement and challenge of synthetic biology. Work at the interface of design and synthetic biology can ask important questions about how new technologies are created, used, applied, and sold, helping us figure out what is good design.

(via Cathal Garvey, via Massively Networked)

Read more:
How To Genetically Modify Yogurt

UCSB Researcher Team Develops Better Understanding of Leukemia Biology | The Daily Nexus

UCSB chemistry and biochemistry professor Norbert Reich and his team of researchers have recently discovered a molecular pathway that may explain the way acute myeloid leukemia develops.

AML is a cancer that occurs inside the bone marrow and destroys healthy blood cells. Eventually, patients become more susceptible to infections and prone to bleeding due to the decrease in the number of normal red and white blood cells as well as platelets.

According to Reich, a mutation in the protein DNMT3A affects the translation of DNA. DNMT3A encodes DNA methyltransferases — enzymes that catalyze the addition of a methyl group to the cytosine residues of CpG dinucleotides. This is the site where cytosine, one of the main bases found in DNA and RNA, can be methylated, or “tagged,” to turn on or off a certain gene. In AML patients, there is a mutation that disrupts the four proteins involved in tagging.

Reich’s research on DNA methyltransferases coincided with another group’s similar medical research regarding AML.

“It just happened to be that the enzyme we were studying applied to AML patients,” Reich said. “DNMT3A is not specific to just AML.”

Since it is involved in mammalian development, the mutations of DNMT3A are also applicable to other types of cancers. Overexpression of this protein has been reported in numerous studies on malignancies including prostate, colorectal and breast tumors.

The team’s research is based on the theory of epigenetics, the study of changes in gene activity that do not involve alterations in the genetic code but are still passed down to at least one successive generation. Every cell in the body has the same DNA yet differs in its epigenome, or tagging pattern. This difference allowed Reich to make the connection between the disrupted tagging pattern and its prevalence in leukemia patients. Upon observing this phenomenon, Reich proposed treating cancer using new methods rather than embracing the traditional “one-fits-all” chemotherapy.

Reich used rats to observe applied epigenetics and observed how a mother rat’s grooming and nursing methods could affect the long-term behavior of her offspring.

“We’ve all heard that the way your mother treats you when you’re younger shapes how you are when you’re older,” Reich said. “But this is the chemistry behind that phenomenon.”

These effects can be correlated with DNA methylation. Epigenetics may be seen as the convergence of the nature versus nurture theory.

“We’re talking about change within one generation,” Reich said. Epigenetics is based on the idea that environmental stressors can elicit a biological response that can be inherited through successive generations. If the environmental stressor is removed, however, the epigenetic marks will eventually fade and revert back to the original DNA programming.

Despite the potential this epigenetics research has for better cancer treatment, a final analysis of the research’s findings and their applicability has yet to be definitively determined.

Read more:
UCSB Researcher Team Develops Better Understanding of Leukemia Biology | The Daily Nexus

GW researchers reveal digital transcriptome of breast cancer

Public release date: 14-Feb-2012
[ | E-mail | Share ]

Contact: Anne Banner
abanner@gwu.edu
202-994-2261
George Washington University Medical Center

GW Cancer Research Team in the Department of Biochemistry and Molecular Biology, in the School of Medicine and Health Sciences, published a study that is the first of its kind to use mRNA sequencing to look at the expression of genome, at a unprecedented resolution at the current time, in three types of breast cancer. The study titled, "Transcriptomic landscape of breast cancer through mRNA sequencing," is published in the Feb. 14 edition of the journal, Scientific Reports, a new open access Nature journal for large volume data.

Breast cancer is the leading cause of cancer death among women, accounting for about 23% of the total cancer cases and about 14% of the cancer deaths worldwide. One of current bottlenecks that hinder the translation of the current gene expression signatures for the benefits of patient is the highly heterogeneous nature of the disease. Therefore, one way to move forward is to identify and gain a deeper insight into the transcriptional regulatory machinery elements, which ultimately are responsible for phenotypic changes, for the next major leap in breast cancer genomic research and treatment. And this is exactly, what was done here, said the senior author and Team Leader Rakesh Kumar, Ph.D., of the project.

Using a sample set of 17 patients with three different types of breast cancer, the GW Research Team which also included collaborators from the John Hopkins College of Medicine and Baylor College of Medicine looked at similarities and differences in their gene expression patterns with a goal to identify biologically relevant, therapeutically important sets of targets in breast cancer. The researchers undertook a high throughput study to define comprehensive digital transcriptome and performed extensive comparative analysis of three groups of breast cancer from the total 1.2 billion reads at various levels of the transcriptional process. The comparative transcriptomic analyses illuminated common as well as differentially expressing transcripts between the three breast cancer groups. Further, high numbers of novel and unannotated transcripts, revealing global breast cancer transcriptomic adaptations in all three breast cancers were also identified.

"We are excited to be a part of this new approach to understand breast cancer. For the first time mRNA sequencing of human breast cancer tissues provides knowledge on central transcriptional regulatory elements, demonstrating the unexplored niches that could change the way breast cancer is previously understood," said lead author Jeyanthy Eswaran, PhD, Director of the McCormick Genomic and Proteomic Center in the department.

While most research today is mainly focused on preselected genes, GW's approach used a completely unbiased approach in order to come up with original snapshot of the breast cancer transcriptome. The GW researchers are working to gain a better understanding of the fundamental occurrences orchestrating the events that lead to a patient suffering from breast cancer. While searching for the highly abundant primary transcript groups which, the team identified osteonectin, guanine nucleotide binding protein beta polypeptide 2-like 1, calnexin calreticulin, ferritin L subunit, and beta-2 microglobulin (B2M) as the top five highly abundant primary transcript group in all three breast cancers. The GW research group is now teaming up with other breast cancer researchers to expend and validate some of the key findings of this work.

"From the on-going, follow-up work in the laboratory, it is clear that the significance of this study has implications beyond the current digital transcriptome of breast cancer as team is actively characterizing novel mutations in protein-coding genes and other elements of human genome that might be relevant in breast cancer," said Dr. Kumar. In addition, the work is likely to influence breast cancer genomics, the transcriptional regulation of cancer, and help built new biologic pathways in breast cancer in the coming years.

###

To view the paper in its entirety, visit: http://www.nature.com/srep/2012/120214/srep00264/full/srep00264.html

About the GW School of Medicine and Health Sciences:

Founded in 1825, the GW School of Medicine and Health Sciences (SMHS) was the first medical school in the nation's capital and is the 11th oldest in the country. Working together in our nation's capital, with integrity and resolve, the GW SMHS is committed to improving the health and well-being of our local, national and global communities. http://www.smhs.gwumc.edu


[ | E-mail | Share ]

 

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

Here is the original post:
GW researchers reveal digital transcriptome of breast cancer

Researchers reveal digital transcriptome of breast cancer

Breast cancer is the leading cause of cancer death among women, accounting for about 23% of the total cancer cases and about 14% of the cancer deaths worldwide. One of current bottlenecks that hinder the translation of the current gene expression signatures for the benefits of patient is the highly heterogeneous nature of the disease. Therefore, one way to move forward is to identify and gain a deeper insight into the transcriptional regulatory machinery elements, which ultimately are responsible for phenotypic changes, for the next major leap in breast cancer genomic research and treatment. And this is exactly, what was done here, said the senior author and Team Leader Rakesh Kumar, Ph.D., of the project.

Using a sample set of 17 patients with three different types of breast cancer, the GW Research Team which also included collaborators from the John Hopkins College of Medicine and Baylor College of Medicine looked at similarities and differences in their gene expression patterns with a goal to identify biologically relevant, therapeutically important sets of targets in breast cancer. The researchers undertook a high throughput study to define comprehensive digital transcriptome and performed extensive comparative analysis of three groups of breast cancer from the total 1.2 billion reads at various levels of the transcriptional process. The comparative transcriptomic analyses illuminated common as well as differentially expressing transcripts between the three breast cancer groups. Further, high numbers of novel and unannotated transcripts, revealing global breast cancer transcriptomic adaptations in all three breast cancers were also identified.

"We are excited to be a part of this new approach to understand breast cancer. For the first time mRNA sequencing of human breast cancer tissues provides knowledge on central transcriptional regulatory elements, demonstrating the unexplored niches that could change the way breast cancer is previously understood," said lead author Jeyanthy Eswaran, PhD, Director of the McCormick Genomic and Proteomic Center in the department.

While most research today is mainly focused on preselected genes, GW's approach used a completely unbiased approach in order to come up with original snapshot of the breast cancer transcriptome. The GW researchers are working to gain a better understanding of the fundamental occurrences orchestrating the events that lead to a patient suffering from breast cancer. While searching for the highly abundant primary transcript groups which, the team identified osteonectin, guanine nucleotide binding protein beta polypeptide 2-like 1, calnexin calreticulin, ferritin L subunit, and beta-2 microglobulin (B2M) as the top five highly abundant primary transcript group in all three breast cancers. The GW research group is now teaming up with other breast cancer researchers to expend and validate some of the key findings of this work.

"From the on-going, follow-up work in the laboratory, it is clear that the significance of this study has implications beyond the current digital transcriptome of breast cancer as team is actively characterizing novel mutations in protein-coding genes and other elements of human genome that might be relevant in breast cancer," said Dr. Kumar. In addition, the work is likely to influence breast cancer genomics, the transcriptional regulation of cancer, and help built new biologic pathways in breast cancer in the coming years.

More information: http://www.nature. … ep00264.html

Provided by George Washington University Medical Center

See the article here:
Researchers reveal digital transcriptome of breast cancer

Opower to Highlight Innovation During Social Media Week Washington

DC (2/15), San Francisco (2/16) and New York (2/16)

ARLINGTON, Va (PRWEB) February 14, 2012

Opower will be discussing its innovations in social media and behavioral science at events on both the West and East Coast during Social Media Week, February 13-17, in Washington, D.C., San Francisco, and New York.

    Washington, D.C.: Wednesday, February 15 at 7:00 p.m., Wayne Lin, Opower’s Director of Product Management, will participate in DC Tech Meetup #11 – Social Media Week Edition to discuss Opower’s social energy application built in partnership with Facebook and the NRDC. The meetup will be held at Sixth & I Historic Synagogue, 600 I Street NW, Washington, D.C. 20001. Following the meetup, Opower will host an afterparty at Rocket Bar, 714 7th Street NW, starting at 8:30 p.m. For more information, visit http://www.meetup.com/DC-Tech-Meetup/events/25773701/ and http://opower.eventbrite.com/.

    San Francisco, CA: Thursday, February 16 from 1:00 – 1:50 p.m., Stephanie Berner, Opower’s Engagement Director, will speak at The Future of Sharing event, which will discuss a study by Beyond that offers a unique and substantiated perspective on the changes that lie ahead for the nature of online sharing. The purpose of the event is to hold an engaged discussion about the study’s findings and to expose different views about how the trends in sharing will shape the way brands reach their desired audiences. At San Francisco State University’s downtown campus, 835 Market Street, 5th Floor, San Francisco, CA 94103. For more information, visit http://socialmediaweek.org/event/?event_id=1386.     Brooklyn, NY: Thursday, February 16 from 6:00 – 11:00 p.m., Wayne Lin will participate in a panel of experts discussing how Opower’s new business models leverage social media to unlock unutilized intent and convert it into tangible action. At Brooklyn Brewery, 79 North 11th Street, Brooklyn, NY 11211. For more information, visit http://socialmediaweek.org/event/?event_id=1023.

Social Media Week is one of the world’s most unique global platforms, offering a series of interconnected activities and conversations around the world on emerging trends in social and mobile media across all major industries with events in 21 cities worldwide.

Opower has more than 220 employees, with offices in Arlington, Virginia, San Francisco, and London. Together with our clients and their customers, we're saving energy, saving money, and helping reduce global carbon emissions.

We’re hiring! Smart, happy people are at the center of our success. We are looking for extraordinary, environmentally-conscious and talented people to join our growing team. In 2012, we will have at least 95 job openings, and more than half of them are on our Engineering and Product teams. Opower offers very competitive compensation packages with a full suite of benefits, and we also offer a $2,500 external referral bonus for critical hires. To find out more, visit opower.com/careers.

About Wayne

Wayne Lin is a Director of Product Management at Opower and is responsible for the company's suite of web products. This includes the recently announced social energy application, launched in partnership with Facebook and NRDC (Natural Resources Defense Council). Prior to joining Opower, Wayne worked at Google in product management and product marketing roles focused on online display advertising technologies. Wayne also founded ecoLightbulbs, a company that sold CFL light bulbs at cost. The company sold more than 13,000 light bulbs, which helped reduce the production of 8MM lbs of CO2 into the atmosphere. Wayne started his career at ZS Associates, a management consulting firm. He received his MBA from Wharton at the University of Pennsylvania and his BA in economics and applied mathematics from Northwestern University. After spending the last 6 years in San Francisco, he is enjoying being back on the East Coast, where there are four full seasons.

About Stephanie

Stephanie Berner is Engagement Director at Opower. Based in San Francisco, Stephanie oversees client operations for Opower’s portfolio of nearly two dozen accounts in the western U.S., where she and her team are responsible for all aspects of delivering Opower’s award-winning behavior-based energy efficiency software and associated programs for utilities including Sempra Energy, Puget Sound Energy, and Pacific Gas & Electric. In a prior role, Ms. Berner was Director of Climate & Energy Services at 3Degrees, a leader in the renewable energy and carbon markets. Her early career included whitewater rafting and ski instructing Sun Valley, Idaho. She holds a BS in Biology from UC Davis and an MBA from the Stanford Graduate School of Business.

About Opower

Opower is the leader in energy information software, providing the utility industry’s only cross-channel platform proven to drive energy efficiency gains on a large scale. Using cutting-edge behavioral science and patent-pending analytics, the Opower platform enables utilities to provide targeted energy data and advice to each customer. More than 60 utilities—including 8 of the 10 largest in the US—partner with Opower to improve the effectiveness of their energy-efficiency portfolios and motivate their customers to become more energy efficient, while dramatically increasing the level of customer engagement and overall customer satisfaction. For utilities with Advanced Metering Infrastructure (AMI), the Opower platform represents a cost-effective way to convert hourly data into measurable energy savings, delivering a clear return on investment directly to customers. Founded in 2007 and privately held, Opower is headquartered in Arlington, Virginia, with a second office in San Francisco, California. For more information, please visit http://www.opower.com.

###

Eric Fleming
Opower
571-384-1292
Email Information

See more here:
Opower to Highlight Innovation During Social Media Week Washington